A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure

Lichtenauer, Michael; Jirak, Peter; Wernly, Bernhard; Paar, Vera; Rohm, Ilonka; Jung, Christian; Schernthaner, Christiana; Kraus, J.; Motloch, Lukas J.; Yılmaz, Atilla; Hoppe, Uta C.; Schulze, P. Christian; Kretzschmar, Daniel; Pistulli, Rudin

doi:10.1016/j.ejim.2017.05.027

Cited by 47 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…sST2 is a cytokine induced by biomechanical strain in cardiac fibroblasts, cardiomyocytes and vascular endothelial cells 195,196 . In a small study, sST2 was significantly higher in patients with DCM than in controls 197 . sST2 has been found to predict the risk of developing heart failure in patients with DCM in several recent studies 193,[198][199][200] .…”

Section: Serum Biomarkersmentioning

confidence: 79%

Dilated cardiomyopathy

Schultheiss

Fairweather

Caforio

et al. 2019

Nat Rev Dis Primers

377

305

View full text Add to dashboard Cite

www.nature.com/nrdp P r i m e r 0123456789(); P r i m e r 0123456789(); 4 | Article citation ID: (2019) 5:32 www.nature.com/nrdp P r i m e r 0123456789(); P r i m e r 0123456789(); P r i m e r 0123456789(); 7 NATURE REVIEwS | DIsEAsE PRIMERs | Article citation ID: (2019) 5:32 P r i m e r 0123456789(); P r i m e r 0123456789(); 9 NATURE REVIEwS | DIsEAsE PRIMERs | Article citation ID: (2019) 5:32 P r i m e r 0123456789(); P r i m e r 0123456789(); P r i m e r 0123456789(); (2019) 5:32 www.nature.com/nrdp P r i m e r 0123456789(); P r i m e r 0123456789();

show abstract

Section: Serum Biomarkersmentioning

confidence: 79%

Dilated cardiomyopathy

Schultheiss

Fairweather

Caforio

et al. 2019

Nat Rev Dis Primers

377

305

View full text Add to dashboard Cite

show abstract

“…Therefore, it might be a useful biomarker to distinguish between GCS‐related cardiac stress and genuine cardiac pathology, since suPAR elevations were described in studies of acute cardiac ischemia and chronic heart failure. It is, however, important to note that suPAR is also elevated in several other chronic diseases and thus cannot be expected to be very specific . Future studies in this field should address direct comparisons between the different patient groups.…”

Section: Discussionmentioning

confidence: 99%

“…It is, however, important to note that suPAR is also elevated in several other chronic diseases and thus cannot be expected to be very specific. 11,25 Future studies in this field should address direct comparisons between the different patient groups.…”

Section: Biomarkers Of Cardiac Injurymentioning

confidence: 99%

Blood markers of cardiac stress after generalized convulsive seizures

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary Objective Generalized convulsive seizures (GCS) are associated with high demands on the cardiovascular system, thereby facilitating cardiac complications. To investigate occurrence, influencing factors, and extent of cardiac stress or injury, the alterations and time course of the latest generation of cardiac blood markers were investigated after documented GCS. Methods Adult patients with refractory epilepsy who underwent video–electroencephalography (EEG) monitoring along with simultaneous one‐lead electrocardiography (ECG) recordings were included. Cardiac biomarkers (cardiac troponin I [cTNI]; high‐sensitive troponin T [hsTNT]; N‐terminal prohormone of brain natriuretic peptide [NT‐proBNP]; copeptin; suppression of tumorigenicity‐2 [SST‐2]; growth differentiation factor 15, [GDF‐15]; soluble urokinase plasminogen activator receptor [suPAR]; and heart‐type fatty acid binding protein [HFABP]) and catecholamines were measured at inclusion and at different time points after GCS. Periictal cardiac properties were assessed by analyzing heart rate (HR), HR variability (HRV), and corrected QT intervals(QTc). Results Thirty‐six GCS (6 generalized‐onset tonic–clonic seizures and 30 focal to bilateral tonic–clonic seizures) were recorded in 30 patients without a history of cardiac or renal disease. Postictal catecholamine levels were elevated more than twofold. A concomitant increase in HR and QTc, as well as a decrease in HRV, was observed. Elevations of cTNI and hsTNT were found in 3 of 30 patients (10%) and 6 of 23 patients (26%), respectively, which were associated with higher dopamine levels. Copeptin was increased considerably after most GCS, whereas SST‐2, HFABP, and GDF‐15 displayed only subtle variations, and suPAR was unaltered in the postictal period. Cardiac symptoms did not occur in any patient. Significance The use of more sensitive biomarkers such as hsTNT suggests that signs of cardiac stress occur in about 25% of the patients with GCS without apparent clinical symptoms. SuPAR may indicate clinically relevant troponin elevations. Copeptin could help to diagnose GCS, but specificity needs to be tested.

show abstract

“…13 Recent studies showed significantly elevated biomarkers (sST2, GDF-15, and H-FABP) in patients with acute myocardial infarction or heart failure than in patients without coronary artery disease and good systolic left ventricular function. Novel cardiovascular biomarkers, such as soluble suppression of tumorigenicity-2 (sST2), growth differentiation factor-15 (GDF-15), cardiac myosin-binding protein C (cardiac MyBP-C), interleukin-8 (IL-8), and heart-type fatty acid-binding protein (H-FABP) have been associated with inflammatory and ischaemic processes in patients suffering from chronic heart failure Moreover, recent trials have shown that these biomarkers could potentially aid in the risk stratification of patients suffering from ischaemic or dilated cardiomyopathy.…”

Section: Cardiovascular Biomarkersmentioning

confidence: 98%

Carcinoid heart disease involving the left heart: a case report and biomarker analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Herein, we report the case of a 67‐year‐old woman who was admitted to our hospital because of dyspnoea and oedema of the lower extremities. Transthoracic echocardiography revealed severe tricuspid and mitral regurgitation, and the leaflets of the tricuspid valve were found to be rigid and almost immobile. The plasma concentrations of serotonin and chromogranin A were elevated, and hence, suspicion for carcinoid heart disease was raised. In addition to the diagnostic workup and medical and surgical treatment, we analysed levels of novel cardiovascular biomarkers throughout the entire follow‐up by means of enzyme‐linked immunosorbent assay. A dopa positron emission tomography (DOPA‐PET) was conducted and showed a neoplasm in the terminal ileum. Tricuspid valve replacement, mitral valve repair, and a closure of the patent foramen ovale (PFO) were conducted. Two months later, hemicolectomy and liver segment resection were performed. The tumour was resected, and the diagnosis of a neuroendocrine tumour (NET) was confirmed. Throughout the follow‐up, we observed a decrease in the plasma levels of novel biomarkers [e.g. interleukin‐8 (IL‐8), soluble suppression of tumorigenicity‐2 (sST2), and heart‐type fatty acid‐binding protein (H‐FABP)] over the follow‐up period. In our case, carcinoid heart disease resulted in a severe tricuspid regurgitation as commonly seen in these patients. Moreover, a pre‐existent mitral regurgitation was likely aggravated by fibrotic remodelling, because a PFO has led to a right‐to‐left shunt and might have caused left heart involvement. As IL‐8 was associated with adverse outcomes in patients with NETs, and sST2 and H‐FABP were associated with adverse outcomes in patients with heart failure previously, these biomarkers could aid in the risk stratification of patients with NET.

show abstract

A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure

Cited by 47 publications

References 32 publications

Dilated cardiomyopathy

Dilated cardiomyopathy

Blood markers of cardiac stress after generalized convulsive seizures

Carcinoid heart disease involving the left heart: a case report and biomarker analysis

Contact Info

Product

Resources

About